For a patient with amyloidosis on Vyndamax (patisiran) being monitored by a hematologist, what are the diagnostic signs and symptoms, recommended laboratory and imaging studies, treatment plan, follow‑up schedule, and key monitoring considerations?

Amyloidosis Management for Patient on Vyndamax

For a patient with amyloidosis on Vyndamax (tafamidis), the hematologist should monitor for disease progression through cardiac biomarkers (NT-proBNP, troponin), assess for neuropathy symptoms, and coordinate multidisciplinary care, as Vyndamax treats cardiac amyloidosis but does not address the underlying clonal disorder in AL amyloidosis or neuropathy in ATTRv amyloidosis.

Critical Clarification: Vyndamax vs. Patisiran

There appears to be confusion in the question. Vyndamax (tafamidis) is NOT the same as patisiran. 1

• Vyndamax/Vyndaqel (tafamidis): TTR stabilizer for ATTR cardiac amyloidosis (ATTR-CM)
• Patisiran: TTR silencer for ATTRv polyneuropathy

The hematologist's role differs significantly based on which medication and which type of amyloidosis:

---

Diagnosis: Signs and Symptoms

Cardiac Manifestations (Primary with Vyndamax)

• Heart failure symptoms: Effort intolerance, shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, leg swelling
• Arrhythmias: Atrial fibrillation, heart block
• Restrictive cardiomyopathy: Preserved ejection fraction with diastolic dysfunction

Neurologic Manifestations 2

Peripheral Neuropathy:

• Bilateral numbness, tingling, burning pain in feet/hands (length-dependent)
• Symptoms worse when lying in bed, improve with walking
• Progressive weakness starting distally

Autonomic Dysfunction:

• Orthostatic hypotension (dizziness on standing)
• Alternating diarrhea/constipation
• Urinary retention
• Erectile dysfunction

Other Neurologic:

• Carpal tunnel syndrome (often precedes polyneuropathy by years)
• Lumbar stenosis symptoms: neurogenic claudication (leg pain/weakness with walking that persists with standing, relieved by sitting/lying—opposite pattern from polyneuropathy)

Red Flag Signs (Highly Specific for AL Amyloidosis) 3

• Macroglossia
• Periorbital purpura ("raccoon eyes")
• These are specific but insensitive

---

Laboratory Workup

For All Amyloidosis Types 4, 5, 6

Cardiac Biomarkers:

• NT-proBNP (>332 ng/L indicates cardiac involvement in AL; used for staging)
• High-sensitivity troponin T or I
• Monitor serially every 3-6 months

To Differentiate AL from ATTR:

• Serum and urine protein electrophoresis with immunofixation
• Serum free light chains (kappa/lambda ratio)
• If monoclonal protein present → AL amyloidosis
• If no monoclonal protein → likely ATTR

For ATTR Subtyping:

• TTR gene sequencing (ATTRv vs ATTRwt)
• Family history assessment

Renal Function:

• Serum creatinine, eGFR
• Urine protein-creatinine ratio
• Urine albumin (screen all MGUS patients) 3

Nutritional Status:

• Modified BMI (weight/height² × serum albumin)
• Albumin, prealbumin

Specific Monitoring if on Patisiran (Not Vyndamax) 2

• Vitamin A supplementation required: 3,000 IU daily (TTR transports retinol)
• Monitor for infusion reactions

Specific Monitoring if on Inotersen 2

• Platelet count weekly (thrombocytopenia risk)
• Serum creatinine and urine protein-creatinine ratio every 2 weeks (glomerulonephritis risk)

---

Imaging Studies

Cardiac Imaging 4

• Echocardiography:

  • Left ventricular wall thickness (≥13 mm suggests cardiac involvement)
  • Interventricular septal thickness
  • Posterior wall thickness
  • Global longitudinal strain (reduced with apical sparing pattern)
  • Diastolic dysfunction assessment

• Cardiac MRI: Late gadolinium enhancement patterns

• Nuclear Imaging (Technetium-99m pyrophosphate scan):

  • Grade 2-3 cardiac uptake with absent monoclonal protein = ATTR-CM diagnosis without biopsy

Repeat Imaging Schedule

• Echocardiography every 6-12 months to assess treatment response and progression

---

Treatment Plan

For ATTR Cardiac Amyloidosis (Vyndamax) 1

Disease-Directed Therapy:

• Vyndamax 61 mg orally once daily OR Vyndaqel 80 mg (four 20-mg capsules) once daily
• Swallow whole, do not crush or cut
• If dose missed: take when remembered or skip and resume regular schedule (do not double dose)
• Indication: Reduce cardiovascular mortality and cardiovascular-related hospitalization in ATTR-CM

Important Limitation:

• Tafamidis is NOT FDA-approved for ATTRv polyneuropathy 2
• If patient has significant neuropathy, consider adding TTR silencer (patisiran, vutrisiran, or inotersen)

For ATTRv Polyneuropathy (If Present) 2

Disease-Directed Therapy (TTR Silencers):

1. Patisiran: 0.3 mg/kg IV every 3 weeks (max 30 mg)

   • Premedicate 60+ minutes before: dexamethasone 10 mg IV, acetaminophen 500 mg, diphenhydramine 50 mg, famotidine 20 mg
   • Vitamin A 3,000 IU daily required

2. Vutrisiran: 25 mg SC every 3 months

   • Vitamin A 3,000 IU daily required

3. Inotersen: 284 mg SC once weekly

   • Vitamin A 3,000 IU daily required
   • Weekly platelet counts
   • Biweekly creatinine and urine protein-creatinine ratio

Key Point: Early treatment is critical—patients treated earlier have better outcomes than those delayed by 1+ year 2

Symptomatic Management 2

Neuropathic Pain:

• First-line: Pregabalin 75 mg twice daily, titrate to 300-600 mg/day
• Alternative: Gabapentin 300 mg at bedtime, titrate to 1,800-3,600 mg/day in 3 divided doses
• Alternative: Duloxetine 20-30 mg daily, titrate to 60-120 mg/day
• Avoid tricyclic antidepressants in patients with autonomic dysfunction (worsens orthostatic hypotension, urinary retention, constipation)

Orthostatic Hypotension:

• Non-pharmacologic: Increased salt/fluid intake, compression stockings, abdominal binders
• Pyridostigmine 30 mg 2-3 times daily (preferred—no fluid retention or supine hypertension risk)
• Alternatives: Midodrine 2.5 mg 3 times daily (titrate to 10 mg 3 times daily) or droxidopa 100 mg 3 times daily (titrate to 600 mg 3 times daily)
• Caution: Midodrine, droxidopa, and fludrocortisone poorly tolerated in heart failure patients 2

Physical Therapy: Essential for maintaining function

For AL Amyloidosis (If Diagnosed) 5, 6

• Daratumumab-cyclophosphamide-bortezomib-dexamethasone (dara-CyBorD): Current standard of care
• Autologous stem cell transplant in eligible patients
• Goal: Profound hematologic response with deepening organ response over time

---

Follow-Up Schedule

Hematologist Monitoring

Every 3 Months:

• NT-proBNP, troponin
• Serum creatinine, eGFR
• Modified BMI
• Assess for new symptoms (neuropathy, autonomic dysfunction)

Every 6 Months:

• Neuropathy Impairment Score (NIS) or modified NIS+7
• Norfolk Quality of Life-Diabetic Neuropathy questionnaire
• Compound Autonomic Dysfunction Test (CADT)
• Polyneuropathy disability (PND) class

Every 6-12 Months:

• Echocardiography
• Reassess free light chains (if AL amyloidosis)

If on Patisiran:

• Monitor for infusion reactions at each infusion
• Confirm vitamin A supplementation compliance

If on Inotersen:

• Weekly platelet counts
• Biweekly creatinine and urine protein-creatinine ratio

Cardiology Coordination

• Regular follow-up for heart failure management
• Avoid standard heart failure medications that may be poorly tolerated (ACE inhibitors, beta-blockers often not beneficial in restrictive cardiomyopathy)

---

Key Monitoring Considerations

What to Look For

Disease Progression:

• Rising NT-proBNP or troponin (cardiac worsening)
• Worsening NIS or PND class (neuropathy progression)
• Declining modified BMI (nutritional decline)
• Worsening quality of life scores

Treatment Response:

• Stabilization or improvement in cardiac biomarkers
• Stabilization or reversal of neuropathy measures 7, 8, 9, 10, 11
• Improved or stable quality of life

Drug Interactions with Vyndamax 1:

• Tafamidis inhibits BCRP transporter
• Monitor for toxicity with: methotrexate, rosuvastatin, imatinib
• Adjust substrate doses if needed

Adverse Events:

• Vyndamax: Generally well-tolerated, no specific monitoring required
• Patisiran: Infusion reactions (16.1% incidence) 2
• Inotersen: Thrombocytopenia, glomerulonephritis 2

Common Pitfalls to Avoid

1. Assuming Vyndamax treats neuropathy: It does not—add TTR silencer if significant polyneuropathy present 2

2. Missing AL amyloidosis: Always check for monoclonal protein—treatment is completely different 5, 6

3. Delaying treatment: Earlier intervention yields better outcomes 2, 8

4. Using standard heart failure medications inappropriately: Many are poorly tolerated in restrictive cardiomyopathy

5. Forgetting vitamin A supplementation: Required with all TTR silencers 2

6. Inadequate monitoring with inotersen: Weekly platelets and biweekly renal function are mandatory 2

7. Using tricyclic antidepressants in autonomic dysfunction: Worsens orthostatic hypotension and other autonomic symptoms 2

Survival Considerations

• Earlier patisiran initiation associated with improved survival 7, 11
• Cardiac involvement is major determinant of survival 3
• Exposure-adjusted mortality rates significantly lower with patisiran treatment 7